H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $60.00 price target on Capricor Therapeutics (NASDAQ: CAPR).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments

Jones Trading on Capricor Therapeutics (CAPR): 'this is the first time we have seen the magnitude of difference in primary outcome'July 27, 2026 2:36 PM B.Riley Downgrades Capricor Therapeutics (CAPR) to NeutralJuly 27, 2026 11:02 AM Capricor disputes FDA briefing materials ahead of deramiocel reviewJuly 27, 2026 11:00 AM Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for DeramiocelJuly 27, 2026 11:00 AM Increasing unusual put option volume: CAPR BETA UCO CRH BKR METC OTLK CIA TCOM EQNRJuly 27, 2026 10:48 AM Oppenheimer Reiterates Capricor Therapeutics (CAPR) at Outperform, 'like the risk-reward'July 27, 2026 10:12 AM Capricor Therapeutics (CAPR) Falls 26% Following FDA Briefing Docs PostJuly 27, 2026 7:55 AM